Compare SMTI & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMTI | IPSC |
|---|---|---|
| Founded | 1982 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.6M | 189.7M |
| IPO Year | 2008 | 2021 |
| Metric | SMTI | IPSC |
|---|---|---|
| Price | $20.56 | $2.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $41.00 | $3.50 |
| AVG Volume (30 Days) | 61.0K | ★ 919.3K |
| Earning Date | 04-20-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.07 |
| EPS | N/A | ★ 0.11 |
| Revenue | ★ $15,586,976.00 | $6,589,000.00 |
| Revenue This Year | $20.66 | $1,590.09 |
| Revenue Next Year | $17.21 | N/A |
| P/E Ratio | ★ N/A | $20.97 |
| Revenue Growth | 32.47 | ★ 194.81 |
| 52 Week Low | $18.29 | $0.34 |
| 52 Week High | $35.70 | $2.71 |
| Indicator | SMTI | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 46.78 | 62.66 |
| Support Level | $20.12 | $0.49 |
| Resistance Level | $26.48 | $2.71 |
| Average True Range (ATR) | 1.05 | 0.17 |
| MACD | 0.20 | 0.02 |
| Stochastic Oscillator | 71.28 | 81.08 |
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.